Commercial Medical Devices

SprintRay Adds Foundation Scanner, Nano Series and GC Resin to Its Digital Dentistry Platform

At 3DNext 2026 in Miami Beach, SprintRay introduced a wireless intraoral scanner built for its ScanOS software, a compact chairside print-wash-cure line and a hybrid ceramic resin developed with GC Corporation.

Ravi MenonOctober 18, 20265 min read11 views
A concept illustration of a compact chairside setup: a small resin printer, wash unit and curing chamber on a clinic counter beside a handheld wireless intraoral scanner.

SprintRay used its 3DNext 2026 event in Miami Beach to introduce a wireless intraoral scanner built for its own ScanOS software, a compact chairside print-wash-cure line, and a restorative resin developed with GC Corporation. The company said it has produced more than 20 million dental parts worldwide.

Taken together, the launches extend SprintRay's connected workflow from scanning and design through production and post-processing — a chain the company had previously held together through third-party integrations.

Foundation scanner ties capture to ScanOS

The scanner, named Foundation, is a wireless, full-colour intraoral device designed for ScanOS. According to SprintRay, it places scanning inside the same account and interface used for design and production, allowing a practice to move from digital capture to a finished case without a separate file export or upload step after scanning. The company said the product will launch officially in the United States, with first shipments expected in November 2026.

"For years, we connected scanning and printing through third-party integrations, but the experience still required practices to move between systems," said Amir Mansouri, Ph.D., co-founder and CEO of SprintRay. He described ScanOS as making scanning a native part of the SprintRay workflow, with Foundation the first intraoral scanner built for it.

Nano Series targets single-case chairside work

NanoPrint, NanoWash and NanoCure form a compact production workflow that occupies less than 30 inches of counter space. SprintRay frames the line around the roughly 80% of chairside print jobs it estimates involve a single patient and a single case. NanoPrint uses a 385 nm light engine; NanoWash automates washing and drying; and NanoCure completes post-processing. AutoPrint and Job Handoff link the production steps and carry case information through the workflow.

The company says the Nano Series supports a broad range of clinical applications through its validated materials library, with specific indications and availability varying by market. Shipments are expected to begin in November 2026 in the United States, Canada, Australia, New Zealand and the European Union, subject to applicable regional regulatory requirements and product availability. NanoWash is not part of the Canadian launch offering.

"We designed the Nano Series to make chairside production more intuitive and practical for the dental team," Mansouri said, adding that the aim was to bring the workflow together in a compact footprint while maintaining the standards clinicians expect from SprintRay.

GC partnership adds a hybrid ceramic resin

SprintRay and GC Corporation have also launched GC GRADIA PREMi, a hybrid ceramic restorative resin developed for the SprintRay Midas Digital Press workflow. The collaboration pairs GC's restorative materials expertise with SprintRay's capsule-based Digital Press platform, with the stated aim of expanding material options for definitive chairside restorations. Specific clinical indications, performance claims and regional availability remain subject to GC's final approved product labelling and regulatory review.

Validation alongside openness

Mansouri framed the partnership strategy as a balance between accepting outside materials and maintaining workflow controls: "Openness matters, but so does validation." He said SprintRay's approach is to work with leading partners to broaden what clinicians can do while keeping rigorous workflow standards.

None of the three announcements disclosed pricing, validated clinical outcome data or confirmed shipping volumes; the scanner and Nano Series timelines are stated as expectations rather than completed launches.